Cell Penetrating Peptides as a Therapeutic Strategy in Chronic Lymphocytic Leukemia

被引:9
|
作者
Arrouss, Issam [1 ]
Decaudin, Didier [2 ,3 ]
Choquet, Sylvain [4 ]
Azar, Nabih [4 ]
Parizot, Christophe [5 ]
Zini, Jean M. [6 ]
Nemati, Fariba [3 ]
Rebollo, Angelita [1 ]
机构
[1] Univ Paris 06, INSERM, UMRS 945, F-75013 Paris, France
[2] Inst Curie, Dept Med Hematol, Paris, France
[3] Inst Curie, Translat Res Dept, Lab Preclin Invest, Paris, France
[4] Hop La Pitie Salpetriere, Serv Hematol Clin, Paris, France
[5] Hop La Pitie Salpetriere, AP HP, Dept Immunol Cellulaire & Tissulaire, Paris, France
[6] Hop St Louis, AP HP, Serv Hematol, Paris, France
来源
PROTEIN AND PEPTIDE LETTERS | 2015年 / 22卷 / 06期
关键词
apoptosis; Caspase-9; CLL; penetrating peptides; PP2A; APOPTOSIS; PROTEINS; SURVIVAL; PATHWAY; TARGET;
D O I
10.2174/0929866522666150216115352
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
PP2A is a serine/threonine phosphatase critical to a number of physiological and developmental processes. In this manuscript, we show that a peptide, specifically blocking the caspase9/PP2A interaction, DPT-C9h, induces apoptosis in primary tumour B cells isolated from peripheral blood mononuclear cells or bone marrow of chronic lymphocytic leukemia (CLL) patients, but not on B cells obtained from healthy donors (HD). Moreover, in both CLL patients and HD, DPT-C9h does not induce apoptosis on T-and NKcells and monocytes. Our results strongly suggest that DPT-C9h peptide has tumour specificity and that caspase-9/PP2Ac interaction constitutes a novel therapeutic approach for the treatment in CLL patients.
引用
收藏
页码:539 / 546
页数:8
相关论文
共 50 条
  • [31] NANOPARTICLE-ASSOCIATED CELL PENETRATING AND CYTOTOXIC PEPTIDES AS A NOVEL THERAPEUTIC STRATEGY FOR MALIGNANT GLIOMA
    Kelly, James
    Gould, Toby W.
    Ward, Jennifer H.
    Shakesheff, Kevin M.
    Dixon, James E.
    Rahman, Ruman
    NEURO-ONCOLOGY, 2015, 17 : 9 - 9
  • [32] A strategy to identify therapeutic candidates for chronic lymphocytic leukemia from a library of FDA approved drugs
    Shen, Min
    Zhang, Yaqin
    Wiestner, Adrian U.
    Ashlock, Melissa A.
    Austin, Christopher P.
    Auld, Douglas S.
    CANCER RESEARCH, 2010, 70
  • [33] Bifunctional Therapeutic Peptides for Targeting Malignant B Cells and Hepatocytes: Proof of Concept in Chronic Lymphocytic Leukemia
    Simon-Gracia, Lorena
    Savier, Eric
    Parizot, Christophe
    Brossas, Jean Yves
    Loisel, Severine
    Teesalu, Tambet
    Conti, Filomena
    Charlotte, Frederic
    Scatton, Olivier
    Aoudjehane, Lynda
    Rebollo, Angelita
    ADVANCED THERAPEUTICS, 2020, 3 (12)
  • [34] Therapeutic delivery using cell-penetrating peptides
    Sawant, Rupa R.
    Patel, Niravkumar R.
    Torchilin, Vladimir P.
    EUROPEAN JOURNAL OF NANOMEDICINE, 2013, 5 (03) : 141 - 158
  • [35] Protein transduction: Cell penetrating peptides and their therapeutic applications
    Wagstaff, KM
    Jans, DA
    CURRENT MEDICINAL CHEMISTRY, 2006, 13 (12) : 1371 - 1387
  • [36] Composite hairy cell leukemia and chronic lymphocytic leukemia
    Papoudou-Bai, Alexandra
    Vassou, Amalia
    Vartholomatos, Georgios
    Briasoulis, Evangelos
    Kanavaros, Panagiotis
    JOURNAL OF BUON, 2016, 21 (04): : 1027 - 1029
  • [37] Conventional therapeutic strategies for relapsed chronic lymphocytic leukemia
    Guieze, Romain
    Ysebaert, Loic
    de Guibert, Sophie
    Dhedin, Nathalie
    Bay, Jacques-Oliver
    Troussard, Xavier
    Tournilhac, Olivier
    BULLETIN DU CANCER, 2012, 99 (12) : 1123 - 1132
  • [38] Hairy cell leukemia coexistent with chronic lymphocytic leukemia
    Francischetti, Ivo M. B.
    Calvo, Katherine R.
    BLOOD, 2019, 133 (11) : 1264 - 1264
  • [39] Plasma cell leukemia mimicking chronic lymphocytic leukemia
    Teriaky, Anouar
    Hsia, Cyrus C.
    BLOOD, 2011, 117 (11) : 2991 - 2991
  • [40] Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia
    Kipps, Thomas J.
    CANCER JOURNAL, 2021, 27 (04): : 306 - 313